Limb fat changes 48 weeks after switching from AZT/3TC to FTC/TDF versus continuing on AZT/3TC. Primary endpoint analysis of the RECOMB trial

被引：0
|
作者：
Martinez, E. [1 ]
Ribera, E. [2 ]
Clotet, B. [3 ]
Estrada, V. [4 ]
Sanz, J. [5 ]
Berenguer, J. [6 ]
Rubio, R. [7 ]
Pulido, F. [7 ]
Larrouse, M. [1 ]
Curran, A. [2 ]
Negredo, E. [3 ]
Arterburn, S. [8 ]
Ferrer, P. [9 ]
Alvarez, M. L. [9 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Hosp Valle De Hebron, Barcelona, Spain
[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Hosp Princesa, Madrid, Spain
[6] Hosp Gen Gregorio Maranon, Madrid, Spain
[7] Hosp 12 Octubre, E-28041 Madrid, Spain
[8] Gilead Sci Inc, Foster City, CA 94404 USA
[9] Gilead Sci SL, Madrid, Spain
来源：
ANTIVIRAL THERAPY | 2008年 / 13卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A47 / A48
页数：2
相关论文
共 11 条
  • [1] A randomized, open-label study to explore the antiretroviral efficacy and tolerability of immediate switching to therapy with AZT/3TC versus continuing ddI/d4T and deferred switching to AZT/3TC in Thai HIV-1 infected population pretreated with ddI/d4T.
    Ruxrungtham, K
    Kroon, EDMB
    Ungsedhapand, C
    Teeratakulpisarn, S
    Ubolyam, S
    van Leeuwen, R
    Buranapraditkun, S
    Sirivichayakul, S
    Lange, JMA
    Cooper, DA
    Phanuphak, P
    AIDS, 1998, 12 : S97 - S97
  • [2] Plasma and cerebrospinal fluid HIV-RNA and drug levels after 48 weeks of follow up of patients treated with AZT/3TC or d4T/3TC with sequential addition of indinavir.
    Foudraine, NA
    Jurriaans, S
    Weverling, GJ
    Hoetelmans, R
    Burger, D
    Von Benthem, B
    Maas, J
    Portegies, P
    Lange, JMA
    AIDS, 1998, 12 : S33 - S33
  • [3] Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) plus Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC plus DTG, and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG
    Bosch, Bronwyn
    Akpomiemie, Godspower
    Chandiwana, Nomathemba
    Sokhela, Simiso
    Hill, Andrew
    McCann, Kaitlyn
    Qavi, Ambar
    Mirchandani, Manya
    Venter, Willem Daniel Francois
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (08) : 1492 - 1495
  • [4] Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF
    Pozniak, A.
    Maggiolo, F.
    Podzamczer, D.
    Yazdanpanah, Y.
    Gupta, S.
    Esser, S.
    Mounzer, K.
    Grossberg, R.
    Post, F.
    Huang, H.
    Acosta, R.
    Baeten, J.
    Hindman, J.
    Martin, H.
    Orkin, C.
    HIV MEDICINE, 2021, 22 : 125 - 125
  • [5] 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
    Y Yazdanpanah
    M-A Khuong-Josses
    L Hocqueloux
    G Pialoux
    J Durant
    B Wynne
    C Granier
    P Tebas
    K Pappa
    S Min
    BMC Infectious Diseases, 14 (Suppl 2)
  • [6] Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
    Johnson, Margaret
    Kumar, Princy
    Molina, Jean-Michel
    Rizzardini, Giuliano
    Cahn, Pedro
    Bickel, Markus
    Mallolas, Josep
    Zhou, Yan
    Morais, Cristiana
    Kumar, Sushma
    Sklar, Peter
    Hanna, George J.
    Hwang, Carey
    Greaves, Wayne
    Belloso, W.
    Cahn, P. E.
    Cassetti, I.
    Lupo, S. H.
    McMahon, J.
    Finlayson, R.
    Bloch, M.
    Read, T.
    Zoufaly, A.
    Rieger, A.
    Haas, B.
    Vandekerckhove, L.
    Florence, E.
    Dewit, S.
    Derdelinckx, I.
    Vandercam, B.
    Smaill, F.
    Walmsley, S.
    Conway, B.
    Szabo, J.
    Gutierrez, J. Onate
    Gerstoft, J.
    Weis, N.
    Larsen, O.
    Nielsen, H.
    Molina, J-M.
    Raffi, F.
    Reynes, J.
    Yazdanpanah, Y.
    Rockstroh, J.
    Bickel, M.
    Jaeger, H.
    Baumgarten, A.
    Bogner, J.
    Arasteh, K.
    Kern, W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 (04) : 463 - 472
  • [7] Non-inferiority of dual-therapy (DT) with darunavir/ ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial
    Pulido, Federico
    Ribera, Esteban
    Lagarde, Maria
    Perez-Valero, Ignacio
    Santos, Jesus
    Iribarren, Jose
    Payeras, Antonio
    Domingo, Pere
    Sanz, Jose
    Cervero, Miguel
    Curran, Adrian
    Rodriguez, Francisco
    Tellez, Maria
    Ryan, Pablo
    Barrufet, Pilar
    Knobel, Hernando
    Rivero, Antonio
    Alejos, Belen
    Yllescas, Maria
    Arribas, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [8] Simplification to abacavir/lamivudine (ABC/3TC) + atazanavir (ATV) from tenofovir/emtricitabine (TDF/FTC) plus ATV/ritonavir (r) maintains viral suppression and improves bone biomarkers: 48 weeks ASSURE study results.
    Wohl, David A.
    Bhatti, Laveeza
    Small, Catherine B.
    Edelstein, Howard E.
    Zhao, Henry
    Margolis, David A.
    Ross, Lisa L.
    Shaefer, Mark S.
    PHARMACOTHERAPY, 2013, 33 (10): : E211 - E212
  • [9] Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study
    Ait-Khaled, M.
    Nascimento, M. C.
    Pappa, K. A.
    Wang, R.
    Wright, J.
    Tenorio, A. R.
    Wynne, B.
    Aboud, M.
    Gartland, M.
    van Wyk, J.
    HIV MEDICINE, 2019, 20 : 20 - 20
  • [10] SOLAR 3D: a prospective comparative study switching from 3-or 4-drug ART to DTG/3TC for maintenance of viral suppression in the setting of current and historical M184V/I and prior virologic failures: 48 week primary endpoint results
    Blick, G.
    Cerreta, E.
    Mancini, G.
    Cosenza, A.
    HIV MEDICINE, 2021, 22 : 122 - 123
12